Orphazyme CEO on trading explosion: "We have no idea what is going on"

The Danish company has not made any announcements over the past 24 hours, so CEO Christophe Bourdon is very surprised at the 300 percent value jump its shares made in the US on Thursday, which rubbed off on the Danish listing on Friday.

CEO Christophe Bourdon is as confused by the developments as anyone. | Photo: Orphazyme / PR

Thursday was a noteworthy day for Orphazyme in every sense of the word.

When trading closed on the Nasdaq exchange in Copenhagen on Thursday, the share price had dropped by 0.2 percent, giving the company a share value of DKK 31.1.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs